{"id":"NCT05020249","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-27","primaryCompletion":"2022-09-05","completion":"2022-09-06","firstPosted":"2021-08-25","resultsPosted":"2024-03-22","lastUpdate":"2025-03-18"},"enrollment":47,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"bimekizumab","otherNames":["BKZ","UCB4940"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bimekizumab arm","type":"EXPERIMENTAL"},{"label":"Placebo arm","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.","primaryOutcome":{"measure":"Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":0,"sd":null},{"arm":"Bimekizumab 320 mg Q4W","deltaMin":81.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":9,"countries":["South Korea"]},"refs":{"pmids":["39328126"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":15},"commonTop":["Corona virus infection","Tinea pedis","Bacteriuria","Eczema","Oedema peripheral"]}}